Literature DB >> 8133619

Tubal ligation, hysterectomy, and risk of ovarian cancer. A prospective study.

S E Hankinson1, D J Hunter, G A Colditz, W C Willett, M J Stampfer, B Rosner, C H Hennekens, F E Speizer.   

Abstract

OBJECTIVE: To assess whether tubal ligation and hysterectomy affect subsequent risk of ovarian cancer.
DESIGN: Prospective cohort study with 12 years of follow-up.
SETTING: United States, multistate. PARTICIPANTS: A total of 121,700 female registered nurses who were 30 to 55 years of age in 1976; the follow-up rate was 90% as of 1988. MAIN OUTCOME MEASURE: Ovarian cancer of epithelial origin confirmed by medical record review.
RESULTS: We observed a strong inverse association between tubal ligation and ovarian cancer, which persisted after adjustment for age, oral contraceptive use, parity, and other ovarian cancer risk factors (multivariate relative risk [RR], 0.33; 95% confidence interval [CI], 0.16 to 0.64). The association was similar when we assessed tubal ligation status at the baseline questionnaire and excluded cases in the first 4 years to eliminate any possible short-term decrease in risk due to screening of the ovaries during ligation surgery. We noted a weaker inverse association between simple hysterectomy and ovarian cancer (RR, 0.67; 95% CI, 0.45 to 1.00). Neither vasectomy nor condom use by a partner was associated with risk of ovarian cancer.
CONCLUSIONS: These data indicate that tubal ligation, and perhaps hysterectomy, may substantially reduce risk of epithelial ovarian cancer.

Entities:  

Mesh:

Year:  1993        PMID: 8133619

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  52 in total

1.  Ovarian cancer in Canada.

Authors:  B Moloughney; J Snider; L Villeneuve
Journal:  CMAJ       Date:  2000-03-07       Impact factor: 8.262

2.  Racial differences in ovarian cancer risk.

Authors:  R B Ness; J A Grisso; J Klapper; R Vergona
Journal:  J Natl Med Assoc       Date:  2000-04       Impact factor: 1.798

Review 3.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

4.  Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer.

Authors:  Thomas A Sellers; Yifan Huang; Julie Cunningham; Ellen L Goode; Rebecca Sutphen; Robert A Vierkant; Linda E Kelemen; Zachary S Fredericksen; Mark Liebow; V Shane Pankratz; Lynn C Hartmann; Jeff Myer; Edwin S Iversen; Joellen M Schildkraut; Catherine Phelan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-02       Impact factor: 4.254

5.  Fallopian tube as main source for ovarian and pelvic (non-endometrial) serous carcinomas.

Authors:  Wenxin Zheng; Oluwole Fadare
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

6.  Preventing ovarian cancer by salpingectomy.

Authors:  W D Foulkes
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

7.  Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006.

Authors:  Tsogzolmaa Dorjgochoo; Xiao-Ou Shu; Hong-Lan Li; Han-Zhu Qian; Gong Yang; Hui Cai; Yu-Tang Gao; Wei Zheng
Journal:  Int J Cancer       Date:  2009-05-15       Impact factor: 7.396

8.  Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.

Authors:  José Augusto Rinck-Junior; Cristiane Oliveira; Gustavo Jacob Lourenço; Regina Aparecida Martinho Sagarra; Sophie Françoise Mauricette Derchain; José Getulio Segalla; Carmen Silvia Passos Lima
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-05       Impact factor: 4.553

Review 9.  Management updates for women with a BRCA1 or BRCA2 mutation.

Authors:  Rachel Nusbaum; Claudine Isaacs
Journal:  Mol Diagn Ther       Date:  2007       Impact factor: 4.074

Review 10.  Current understanding of risk factors for ovarian cancer.

Authors:  Thanasak Sueblinvong; Michael E Carney
Journal:  Curr Treat Options Oncol       Date:  2009-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.